Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831
- Citation:
- Cancer Res vol 72 (24 supplement) S5
- Meeting Instance:
- SABCS 2012
- Year:
- 2012
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Comprehensive
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2194
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- E. H. Romond V. J. Suman J.-H. Jeong G. Sledge C. E. Geyer Jr S. Martino P. Rastogi J. Gralow S. M. Swain E. Winer G. Colon-Otero C. Hudis S. Paik N. E. Davidson E. Mamounas J. Zujewski N. Wolmark E. A. Perez
- Networks:
- Study
- NCCTG-N9831
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: